Moderna's COVID-Flu Vaccine Shows Stronger Immune Response Than Individual Shots, Late-Stage Trial Finds

Moderna has announced promising data on a combination COVID-flu vaccine. This trial tested the combination vaccine in two groups of roughly 4,000 adults, one aged 65 and older and other between 50 and 64 years, and used blood tests to assess the strength of immune response generated by two different vaccines for the viruses administered at the same time. Moderna has not published data from the trial or opened it up to external scrutiny but said it plans to present data at an upcoming medical conference and ...